# Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation

> **NCT02338232** · NA · TERMINATED · sponsor: **Hackensack Meridian Health** · enrollment: 32 (actual)

## Conditions studied

- GVHD

## Interventions

- **DRUG:** Telmisartan

## Key facts

- **NCT ID:** NCT02338232
- **Lead sponsor:** Hackensack Meridian Health
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07-07
- **Primary completion:** 2023-01-05
- **Final completion:** 2023-01-05
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Lack of Accrual
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02338232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02338232, "Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02338232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*